KerriAnn Millar - Cue Biopharma Principal Financial Officer
| CUE Stock | USD 1.22 0.13 11.93% |
Executive
Ms. KerriAnn Millar is Principal Financial Officer of the company. She joined the Company in September 2017 as Corporationrationrate Controller. Prior to joining the Company, Ms. Millar served as Corporationrationrate Controller of Flexion Therapeutics, Inc., a biopharmaceutical company focused on the development of local therapies for the treatment of patients with musculoskeletal conditions, such as osteoarthritis, from March 2014 to September 2017. From May 2005 to March 2014, she served as Finance Specialist for Curis, Inc., a biotechnology company focused on treatments for cancer since 2018.
| Age | 54 |
| Tenure | 6 years |
| Address | 40 Guest Street, Boston, MA, United States, 02135 |
| Phone | 617 949 2680 |
| Web | https://www.cuebiopharma.com |
Cue Biopharma Management Efficiency
The company has Return on Asset of (0.5211) % which means that on every $100 spent on assets, it lost $0.5211. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (1.3887) %, meaning that it generated no profit with money invested by stockholders. Cue Biopharma's management efficiency ratios could be used to measure how well Cue Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. As of November 29, 2024, Return On Tangible Assets is expected to decline to -0.87. In addition to that, Return On Capital Employed is expected to decline to -1.23. At present, Cue Biopharma's Total Current Assets are projected to increase significantly based on the last few years of reporting.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Karen MS | Coya Therapeutics, Common | N/A | |
| Melita Jung | Terns Pharmaceuticals | 47 | |
| Michael McNamara | In8bio Inc | N/A | |
| Robert Andrade | Fennec Pharmaceuticals | 49 | |
| MS BS | Lantern Pharma | N/A | |
| John Doyle | Cognition Therapeutics | 47 | |
| Ann Hargraves | Tscan Therapeutics | N/A | |
| Cagan Gurer | Tscan Therapeutics | N/A | |
| Nicole Leber | Lantern Pharma | N/A | |
| Zamaneh MD | Tff Pharmaceuticals | 60 | |
| Zoran JD | Tscan Therapeutics | 54 | |
| Leiden MBA | Tscan Therapeutics | N/A | |
| Maria MBA | Dermata Therapeutics | 73 | |
| Debra Sieminski | Terns Pharmaceuticals | N/A | |
| Aaron Thome | Coya Therapeutics, Common | N/A | |
| Jason Amello | Tscan Therapeutics | 56 | |
| MBA MD | X4 Pharmaceuticals | 62 | |
| Valerie Morisset | Eliem Therapeutics | 54 | |
| Christiana MBA | Fennec Pharmaceuticals | N/A | |
| Pharm MPH | X4 Pharmaceuticals | N/A | |
| Maria Rubin | PolyPid | N/A | |
Management Performance
| Return On Equity | -1.39 | ||||
| Return On Asset | -0.52 |
Cue Biopharma Leadership Team
Elected by the shareholders, the Cue Biopharma's board of directors comprises two types of representatives: Cue Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cue. The board's role is to monitor Cue Biopharma's management team and ensure that shareholders' interests are well served. Cue Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cue Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| JD MSc, CEO Director | ||
| Kenneth MD, Acting Officer | ||
| Steven Almo, CoFounder Board | ||
| Matteo MD, Chief Officer | ||
| Dr III, CoFounder | ||
| Lucinda Warren, Chief Officer | ||
| MSc JD, CEO Director | ||
| George Zavoico, VP Development | ||
| KerriAnn Millar, Principal Financial Officer | ||
| MSE JD, General VP | ||
| Rodolfo Chaparro, Executive Vice President - Head of Immunology | ||
| Anish Suri, President Officer |
Cue Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cue Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.39 | ||||
| Return On Asset | -0.52 | ||||
| Operating Margin | (3.91) % | ||||
| Current Valuation | 54.38 M | ||||
| Shares Outstanding | 63.35 M | ||||
| Shares Owned By Insiders | 0.54 % | ||||
| Shares Owned By Institutions | 23.59 % | ||||
| Number Of Shares Shorted | 1.07 M | ||||
| Price To Earning | (2.17) X | ||||
| Price To Book | 3.05 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Cue Biopharma is a strong investment it is important to analyze Cue Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cue Biopharma's future performance. For an informed investment choice regarding Cue Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cue Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. For information on how to trade Cue Stock refer to our How to Trade Cue Stock guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cue Biopharma. If investors know Cue will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cue Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.91) | Revenue Per Share 0.172 | Quarterly Revenue Growth 0.923 | Return On Assets (0.52) | Return On Equity (1.39) |
The market value of Cue Biopharma is measured differently than its book value, which is the value of Cue that is recorded on the company's balance sheet. Investors also form their own opinion of Cue Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Cue Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cue Biopharma's market value can be influenced by many factors that don't directly affect Cue Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cue Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cue Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cue Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.